Pancreatic Cancer Market Segmentation:
Type Segment Analysis
The chemotherapy segment is estimated to account for a 55% share of the global pancreatic cancer market by 2035. Despite the side effects, this method of isolating carcinoma cells in tumor formation is still one of the most prescribed and highly effective curatives. In this regard, a nationwide population-based study, conducted in Korea, was published by ScienceDirect in August 2023, concluding the proportion of PC patients undergoing chemotherapy to be 26.6%. It also mentioned that survival rates were significantly improved by following this approach. Furthermore, the use of this curative in several disciplines, such as adjuvants and combination therapies, is also a reason behind this segment’s proprietorship in revenue generation for this sector.
Affected Area Segment Analysis
The exocrine segment is expected to hold 60% of the revenue share in the pancreatic cancer market over the assessed timeline. The pancreas is mostly composed of exocrine cells compared to endocrine cells in the body, which is estimated to position this segment as the leading revenue generator in this field. Testifying this fact, NLM discovered over 90.0% of pancreatic cancers across the world to be pancreatic ductal adenocarcinomas (PDACs), 80.0% among which are diagnosed with advanced-stage disease, published in an article in June 2023. It also mentioned that the 5-year survival rate of PDAC cases is only 11.0%, highlighting the priority of clinical explorations in this segment.
Our in-depth analysis of the global pancreatic cancer market includes the following segments:
|
Type |
|
|
Affected Areas |
|
|
End User |
|
